CONTENTS:

• COVID-19 vaccines and ITP: Should patients be vaccinated?
• Anxiety In Adult Patients Living With ITP Stratified Across Different Treatment Types and Groups: A Survey study by PDSA
• Importance Of Glycoside Residues On Haemostatsis of Patients With Immune Thrombocytopenia
• Tapering Thrombopoietin Receptor Agonists In Primary Immune Thrombocytopenia: Recommendations Based On The RAND/UCLA Modified Delphi Panel Method

CONTENTS:

• Phase 1/2 Trial Shows Promise For Rilzabrutinib In Patients With ITP
• Fostamatinib Is An Effective Second-Line Therapy In Patients With Immune Thrombocytopenia
• Health Canada Approves TAVALISSE For The Treatment Of Adults With Chronic Immune Thrombocytopenia

CONTENTS:

• Perioperative Oral Eltrombopag Versus Intravenous Immunoglobulin In Patients With Immune Thrombocytopenia: A Non-Inferiority, Multicenter, Randomized Trial
• NIH Launches Trial of Rigel Drug for Severe COVID-19 and Octapharma launches trial for intravenous immunoglobulin (IVIG) as Potential Treatment for COVID-19

In light of the COVID-19 global pandemic, the 25th Congress of the European Hematology Association (EHA) scheduled to take place in Frankfurt, Germany switched their annual meeting to a virtual meeting held online between June 11-21, 2020. PDSA staff and members of the PDSA medical advisory board participated in this prestigious meeting by submitting multiple abstracts that were accepted in e-poster format. PDSA President and CEO, Caroline Kruse, and Research Coordinator, Alexandra Kruse, are authors on all of the following abstracts.

CONTENTS:

• Higher Symptom Burden In Patients With Immune Thrombocytopenia Experiencing Fatigue: Results From The ITP World Impact Survey (I-WISH)
• Patient’s Reported Perceptions On Satisfaction With Immune Thrombocytopenia Treatments: Results From The ITP World Impact Survey (I-WISH)

CONTENTS:

• Fostamatinib Is An Effective Second-Line Therapy In Patients With Immune Thrombocytopenia
• A Patient’s Perspective On Impact of Immune Thrombocytopenia On Emotional Wellbeing: ITP World Impact Survey (I-WISH)

In light of the COVID-19 global pandemic, the 25th Congress of the European Hematology Association (EHA) scheduled to take place in Frankfurt, Germany switched their annual meeting to a virtual meeting held online between June 11-21, 2020. PDSA staff and members of the PDSA’s medical advisory board participated in this prestigious meeting by submitting multiple abstracts that were accepted in e-poster format. The following summaries are from two insightful e-poster abstracts presented at EHA.

CONTENTS:

• Long-Term Overuse of Corticosteroids in Patients with Immune Thrombocytopenia: A Real-World Analysis of a US Claims Database
• Mental Health and Physical Function in Pediatric Immune Thrombocytopenia (ITP): Quality of Life Data from the Platelet Disorder Support Association (PDSA) Patient Registry

CONTENTS:

• Risk of Systemic Lupus Erythematosus in Patients with Idiopathic* Thrombocytopenic Purpura: A Population-Based Cohort Story
• Fatigue, Executive Function and Psychological Effects in Children with Immune Thrombocytopenia: A Cross-Sectional Study

Living with ITP can be frightening for patients and their families and these worries have been worsened in the setting of COVID19. One of the factors that makes ITP so challenging is that it is very hard to predict if and when bleeding may occur, and if bleeding might be severe, even life-threatening. This uncertainty makes it difficult to decide which medication to select, and when and how to deploy it to treat patients. The following two articles discuss risk factors that could help in predicting the development of severe bleeds.

CONTENTS:

• Risk Factors for Skin, Mucosal, and Organ Bleeding in Adults with Primary ITP: A Nationwide Study in Japan
• Management of Major Bleeds in Patients with Immune Thrombocytopenia

CONTENTS:

• PDSA Medical Advisor Leading World’s Largest Clinical Trial of a Potential Treatment for COVID-19
• Immune Thrombocytopenia: a case study from the New England Journal of Medicine

CONTENTS:

• Severe Immune Thrombocytopenia Complicated by Intracerebral Haemorrhage Associated with Coronavirus Infection: A Case Report and Literature Review
• Immune Thrombocytopenia in Very Elderly Patients: Particularities in Presentation and Management. Results from the Multicenter Prospective Carmen-France Registry

In this issue of the e-news, we report on a few additional abstracts that were presented at the December (2019) American Society of Hematology meeting, in Orlando, Florida. The ASH abstract numbers are shown in parentheses. You can search on the number and read the complete abstract at: https://ashpublications.org/blood/issue/134/Supplement_1

CONTENTS:

• Racial Variation in ITP Prevalence and Rate of Chronic Disease Suggests Biological Differences (130418)
• High-Dose Dexamethasone (HD-DXM) Plus Oseltamivir vs High-Dose Dexamethasone for Treatment of Adult Primary Immune Thrombocytopenia: interim analysis of a prospective, multi-center, randomized controlled trial (121825)

Innovative ITP Research from the 2019 American Society of Hematology (ASH) Annual Meeting

This year’s 2019 ASH meeting, held December 7-10 in Orlando (Florida), attracted over 30,000 clinicians, scientists, pharmaceutical company personnel and even investment analysts worldwide to share ground-breaking research in the field of hematology. The conference included the annual ITP breakfast meeting, coordinated by PDSA and four of PDSA’s Medical Advisors, Dr. James Bussel, Dr. Nichola Cooper, Dr. Michele Lambert and Dr. John Semple. Thirteen hematology experts were invited to present their leading-edge ITP research. In this e-news issue, we report on experimental therapies for ITP for which updates on or new clinical trials were presented.

CONTENTS:

• Eltrombopag: More Than Just a Thrombopoietin Receptor Agonist (TPO-RA) in Immune Thrombocytopenia (12284)
• Phase 1/11, Open-Label, Adaptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients with Relapsed/Refractory Primary or Secondary Immune Thrombocytopenia (122336)